JP2013515748A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515748A5
JP2013515748A5 JP2012546257A JP2012546257A JP2013515748A5 JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5 JP 2012546257 A JP2012546257 A JP 2012546257A JP 2012546257 A JP2012546257 A JP 2012546257A JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5
Authority
JP
Japan
Prior art keywords
virus
influenza
particle
envelope
influenza antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515748A (ja
JP6073031B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/062217 external-priority patent/WO2011090712A2/en
Publication of JP2013515748A publication Critical patent/JP2013515748A/ja
Publication of JP2013515748A5 publication Critical patent/JP2013515748A5/ja
Application granted granted Critical
Publication of JP6073031B2 publication Critical patent/JP6073031B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546257A 2009-12-28 2010-12-28 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 Expired - Fee Related JP6073031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29043809P 2009-12-28 2009-12-28
US61/290,438 2009-12-28
PCT/US2010/062217 WO2011090712A2 (en) 2009-12-28 2010-12-28 Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016193457A Division JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Publications (3)

Publication Number Publication Date
JP2013515748A JP2013515748A (ja) 2013-05-09
JP2013515748A5 true JP2013515748A5 (https=) 2014-01-09
JP6073031B2 JP6073031B2 (ja) 2017-02-01

Family

ID=44307476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546257A Expired - Fee Related JP6073031B2 (ja) 2009-12-28 2010-12-28 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
JP2016193457A Pending JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016193457A Pending JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Country Status (4)

Country Link
US (2) US20130028933A1 (https=)
EP (1) EP2519539A4 (https=)
JP (2) JP6073031B2 (https=)
WO (1) WO2011090712A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
AP2015008733A0 (en) * 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
AU2014368594B2 (en) * 2013-12-19 2020-03-05 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
US10100093B2 (en) * 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
WO2016154055A1 (en) * 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
JP7221049B2 (ja) 2015-11-19 2023-02-13 ノバルティス アーゲー レンチウイルス調製物の安定化のための緩衝液
CN109803640B (zh) * 2016-08-10 2022-01-04 赛特瑞恩股份有限公司 稳定的液体抗流感病毒抗体医药调配物
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
KR20230039766A (ko) * 2017-12-20 2023-03-21 조에티스 서비시즈 엘엘씨 Hendra 및 Nipah 바이러스 감염을 대비한 백신
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
DE69520278T2 (de) * 1995-11-25 2001-09-20 Study Center Of Allergy Projects (S.C.A.P.), Haarlem Verwendung eines Disaccharids als Stabilisator für flüssige Proteinmischungen sowie ein Disaccharid enthaltende flüssige Proteinmischungen
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
MXPA02012254A (es) * 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
CN1745170A (zh) * 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
KR20060135931A (ko) * 2004-04-01 2006-12-29 알자 코포레이션 인플루엔자 백신의 경피전달 장치 및 방법
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
WO2007044610A2 (en) * 2005-10-07 2007-04-19 Avatar Vaccines, Inc. Virus-like particles and methods of use
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
WO2008011120A2 (en) * 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
EP2044198A4 (en) * 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
WO2008061243A2 (en) * 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
CA2716340A1 (en) * 2008-02-21 2009-08-27 Biological Mimetics, Inc. Immunogenic influenza composition
WO2009108689A1 (en) * 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
KR20120131725A (ko) * 2011-05-26 2012-12-05 건국대학교 산학협력단 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신
CA2863949C (en) * 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Similar Documents

Publication Publication Date Title
JP2013515748A5 (https=)
Wang et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
US20230390381A1 (en) Immunogenic combinations
US12440550B2 (en) Immunogenic compositions and uses thereof
Rossey et al. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
JP2014503206A5 (https=)
Simnani et al. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
JP2023081859A (ja) コロナウイルスワクチン
JP2020528911A5 (https=)
CN107106673A (zh) 用于增强免疫应答的方法和组合物
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
Wang et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines
TW202430206A (zh) 組合疫苗
CN116650633A (zh) 冠状病毒疫苗
Wong et al. Influenza vaccination: options and issues
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
Gattinger et al. Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)
JP2024523329A (ja) ウイルス性疾患用の温度制御可能な自己複製ｒｎａワクチン
Lundstrom COVID-19 vaccines: where did we stand at the end of 2023? Viruses. 2024; 16: 203
Lupascu et al. Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review
Lundstrom COVID-19 Vaccines: Where Do We Stand at the End of 2023?
HK40060960A (en) Immunogenic combinations
Ashraf et al. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines 2021, 9, 171
WO2026006624A1 (en) Stabilized and atomic layer deposition (ald)-coated lipid assembly-free polynucleotide-containing microparticles and uses thereof
HK40097472A (zh) 冠状病毒疫苗